1. Relationship Between the Lipidome Profile and Disease Activity in Patients with Rheumatoid Arthritis.
- Author
-
Masuoka S, Nishio J, Yamada S, Saito K, Kaneko K, Kaburaki M, Tanaka N, Sato H, Muraoka S, Kawazoe M, Mizutani S, Furukawa K, Ishii-Watabe A, Kawai S, Saito Y, and Nanki T
- Subjects
- Humans, Middle Aged, Female, Male, Stearic Acids metabolism, Stearic Acids blood, Palmitic Acid, Aged, Lipids blood, Blood Sedimentation, Osteoclasts metabolism, Adult, Biomarkers blood, Biomarkers metabolism, Severity of Illness Index, Arthritis, Rheumatoid metabolism, Arthritis, Rheumatoid blood, Lipidomics
- Abstract
Lipid mediators have been suggested to play important roles in the pathogenesis of rheumatoid arthritis (RA). Lipidomics has recently allowed for the comprehensive analysis of lipids and has revealed the potential of lipids as biomarkers for the early diagnosis of RA and prediction of therapeutic responses. However, the relationship between disease activity and the lipid profile in RA remains unclear. In the present study, we performed a plasma lipidomic analysis of 278 patients with RA during treatment and examined relationships with disease activity using the Disease Activity Score in 28 joints (DAS28)-erythrocyte sedimentation rate (ESR). In all patients, five lipids positively correlated and seven lipids negatively correlated with DAS28-ESR. Stearic acid [FA(18:0)] (r = -0.45) and palmitic acid [FA(16:0)] (r = -0.38) showed strong negative correlations. After adjustments for age, body mass index (BMI), and medications, stearic acid, palmitic acid, bilirubin, and lysophosphatidylcholines negatively correlated with disease activity. Stearic acid inhibited osteoclast differentiation from peripheral blood monocytes in in vitro experiments, suggesting its contribution to RA disease activity by affecting bone metabolism. These results indicate that the lipid profile correlates with the disease activity of RA and also that some lipids may be involved in the pathogenesis of RA., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF